... or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2025 Hypoglycemia Insulin Beta cells Diazoxide Hyperinsulinemic...

... by tracheostomy. HH was diagnosed at a median age of 222 days (median, range 36–594) with postprandial hypoglycaemia (4/6 patients) or fasting hypoglycaemia (2/6 patients). Two patients were treated with diazoxide monotherapy; one with diazoxide and overnight continuous gastrostomy feeds; one with acarbose...

... Gesù from 1985 to 2022. Results: Hypoglycemia occurred within the first year of life in 85.5% of patients, median time to diagnosis was 1 day (IQR 14 days). Ninety-two percent of patients were treated with diazoxide: 66.9% were responsive. Octreotide was administered to 28.6% of patients: 61.4% were...

...Lucy A. Hastings; John Preddy; Michael McCready; Kristen Neville; Charles F. Verge Background: Diazoxide is widely used to manage congenital hyperinsulinism and is generally well tolerated. Pericardial effusion is not a recognized side effect of diazoxide, apart from 2 single case reports. Case...

...Paul Thornton; Lisa Truong; Courtney Reynolds; Tyler Hamby; Jonathan Nedrelow Introduction: Diazoxide is the first line and only Federal Drug Agency approved pharmacological agent for the treatment of hyperinsulinism. Its use has increased over the years to include patients with various genetic...

.... Insulin secretion was studied in pancreatic islets and in mouse islets treated with an inhibitor of KDM6A , an X chromosome gene associated with hyperinsulinism in Kabuki syndrome. Results: Hyperinsulinism was diagnosed in 12 girls with Turner syndrome. Six were diazoxide-unresponsive; 3 had...

...Rika Kizu; Kazuko Nishimura; Reiko Sato; Kenjiro Kosaki; Toshiaki Tanaka; Yusuke Tanigawara; Tomonobu Hasegawa Background: Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI...

... includes use of oral diazoxide (a K ATP channel agonist) and daily injectable octreotide (somatostatin analogue) therapy. However, diazoxide is associated with severe sideeffects such as coarse facies, hypertrichosis and psychosocial/compliance issues in adolescents. Lanreotide (a long-acting somatostatin...

...Caroline Ponmani; Hannah Gannon; Khalid Hussain; Senthil Senniappan Background/Aims: Hyperinsulinaemic hypoglycaemia (HH) is the most common cause of severe and persistent hypoglycaemia in the neonatal period. Diazoxide, a K ATP channel activator, is the first line of treatment for patients with HH...

... hyperinsulinism and hypoglycemia in the children and a milder but abnormal response in the mother. To evaluate the therapeutic effects and to study the mechanism of hyperinsulinism in LIH, the leucine test was repeated under treatment with diphenylhydantoin, oxprenolol (a beta-blocker), and diazoxide. Diazoxide...

... release by epinephrine, diazoxide or omission of Ca + + resulted in considerably elevated islet levels of glucose-6-phosphate. A reduced availability of Ca + + may be a common denominator forthis effect on glucose-6-phosphate. 21 11 2008 © 1971 S. Karger AG, Basel 1971 Copyright / Drug...